ArticlePloS one2012
Establishment of induced pluripotent stem cells from centenarians for neurodegenerative disease research.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 81 citations in OpenAlex.
- Strategies for modeling aging and age-related diseases.npj aging · 2024Review
- Partial cellular reprogramming: A deep dive into an emerging rejuvenation technology.Aging cell · 2024Review
- Clinical Potential of Cellular Material Sources in the Generation of iPSC-Based Products for the Regeneration of Articular Cartilage.International journal of molecular sciences · 2023Review
- Dietary Plant Polyphenols as the Potential Drugs in Neurodegenerative Diseases: Current Evidence, Advances, and Opportunities.Oxidative medicine and cellular longevity · 2022Review
- Brain organoids: A promising model to assess oxidative stress-induced central nervous system damage.Developmental neurobiology · 2021Review
- Metabolic disorder in Alzheimer's disease.Metabolic brain disease · 2021Review
- Induced Tissue-Specific Stem Cells (iTSCs): Their Generation and Possible Use in Regenerative Medicine.Pharmaceutics · 2021Review
- Review
- Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.FEBS open bio · 2021Article
- Heterochromatin: an epigenetic point of view in aging.Experimental & molecular medicine · 2020Review
- The ageing epigenome and its rejuvenation.Nature reviews. Molecular cell biology · 2020Review
- Current status and future prospects of stem cell therapy in Alzheimer's disease.Neural regeneration research · 2020Article
- Important advances in Alzheimer's disease from the use of induced pluripotent stem cells.Journal of biomedical science · 2019Review
- Epigenetic changes during aging and their reprogramming potential.Critical reviews in biochemistry and molecular biology · 2019Review
- Epigenetic Enzymes, Age, and Ancestry Regulate the Efficiency of Human iPSC Reprogramming.Stem cells (Dayton, Ohio) · 2018Article
- A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer's disease.Nature neuroscience · 2018Article
- Human Neurospheroid Arrays for In Vitro Studies of Alzheimer's Disease.Scientific reports · 2018Article
- Age-Related Epigenetic Derangement upon Reprogramming and Differentiation of Cells from the Elderly.Genes · 2018Review
- Silencing of the lncRNA Zeb2-NAT facilitates reprogramming of aged fibroblasts and safeguards stem cell pluripotency.Nature communications · 2018Article
- Age Is Relative-Impact of Donor Age on Induced Pluripotent Stem Cell-Derived Cell Functionality.Frontiers in cardiovascular medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Induced pluripotent stem cell (iPSC) technology can be used to model human disorders, create cell-based models of human diseases, including neurodegenerative diseases, and in establishing therapeutic strategies. To detect subtle cellular abnormalities associated with common late-onset disease in iPSCs, valid control iPSCs derived from healthy donors free of serious late-onset diseases are necessary. Here, we report the generation of iPSCs from fibroblasts obtained immediately postmortem from centenarian donors (106- and 109-years-old) who were extremely healthy until an advanced age. The iPSCs were generated using a conventional method involving OCT4, SOX2, KLF4, and c-MYC, and then differentiated into neuronal cells using a neurosphere method. The expression of molecules that play critical roles in late-onset neurodegenerative diseases by neurons differentiated from the centenarian-iPSCs was compared to that of neurons differentiated from iPSCs derived from familial Alzheimer's disease and familial Parkinson's disease (PARK4: triplication of the α synuclein gene) patients. The results indicated that our series of iPSCs would be useful in neurodegeneration research. The iPSCs we describe, which were derived from donors with exceptional longevity who were presumed to have no serious disease risk factors, would be useful in longevity research and as valid super-controls for use in studies of various late-onset diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.